Raymond James & Associates Has $201.04 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Raymond James & Associates reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 4.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 794,957 shares of the medical research company’s stock after selling 39,358 shares during the period. Raymond James & Associates’ holdings in IQVIA were worth $201,037,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Jag Capital Management LLC boosted its holdings in shares of IQVIA by 0.4% in the 4th quarter. Jag Capital Management LLC now owns 11,401 shares of the medical research company’s stock valued at $2,638,000 after buying an additional 49 shares during the last quarter. Laurel Wealth Advisors LLC grew its position in shares of IQVIA by 1.1% in the 3rd quarter. Laurel Wealth Advisors LLC now owns 4,710 shares of the medical research company’s stock valued at $927,000 after acquiring an additional 50 shares during the period. Raleigh Capital Management Inc. increased its stake in shares of IQVIA by 4.5% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,157 shares of the medical research company’s stock worth $268,000 after purchasing an additional 50 shares during the last quarter. Parkside Financial Bank & Trust grew its holdings in IQVIA by 18.1% during the third quarter. Parkside Financial Bank & Trust now owns 346 shares of the medical research company’s stock worth $68,000 after purchasing an additional 53 shares during the period. Finally, Cypress Wealth Services LLC increased its position in IQVIA by 5.3% during the first quarter. Cypress Wealth Services LLC now owns 1,101 shares of the medical research company’s stock worth $278,000 after buying an additional 55 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of recent analyst reports. Evercore ISI raised their price objective on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a research report on Thursday, February 15th. Leerink Partnrs reissued an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Guggenheim lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Truist Financial lifted their target price on IQVIA from $286.00 to $297.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $256.80.

IQVIA Price Performance

Shares of IQVIA stock traded up $0.90 on Friday, reaching $234.88. 697,640 shares of the stock were exchanged, compared to its average volume of 761,918. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86. The firm has a market cap of $42.63 billion, a PE ratio of 32.22, a P/E/G ratio of 2.26 and a beta of 1.50. The firm’s 50 day moving average is $245.28 and its 200-day moving average is $223.02. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73.

IQVIA (NYSE:IQV) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The firm had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. During the same period in the prior year, the company earned $2.54 earnings per share. The company’s quarterly revenue was up 3.5% on a year-over-year basis. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now directly owns 20,836 shares in the company, valued at approximately $5,031,894. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the sale, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Eric Sherbet sold 1,000 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.